Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

Novel oral anticoagulants and reversal agents: Considerations for clinical development

(2015) Troy C. Sarich et al.   AMERICAN HEART JOURNAL

Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and BleedingCLINICAL PERSPECTIVE

(2015) Peter Brønnum Nielsen et al.   CIRCULATION

Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants

(2015) Andres Enriquez et al.   EUROPACE

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

(2015) Hein Heidbuchel et al.   EUROPACE

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

(2015) Stephan Glund et al.   LANCET

Idarucizumab for Dabigatran Reversal

(2015) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

(2015) Paul A. Reilly et al.   THROMBOSIS AND HAEMOSTASIS

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

(2015) Viktoria Moschetti et al.   THROMBOSIS AND HAEMOSTASIS

A synthetic small molecule antidote for anticoagulants

(2014) S. Bakhru et al.   EUROPEAN HEART JOURNAL

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

(2014) Elaine M. Hylek et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban

(2014) Jack E. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment

(2014) Joji Hagii et al.   STROKE

Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications

(2013) Veronica Yank et al.   ANNALS OF INTERNAL MEDICINE

A specific antidote for dabigatran: functional and structural characterization

(2013) F. Schiele et al.   BLOOD

Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

(2013) Ammar Majeed et al.   CIRCULATION

Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding

(2013) Ravi Sarode et al.   CIRCULATION

EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary†

(2013) Hein Heidbuchel et al.   EUROPEAN HEART JOURNAL

Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation

(2013) Torben Bjerregaard Larsen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Translational medicine advances in von Willebrand disease

(2013) D. Lillicrap   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Antidotes edge closer to reversing effects of new blood thinners

(2013) Elie Dolgin   NATURE MEDICINE

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

(2013) Genmin Lu et al.   NATURE MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation

(2013) Pilar Gallego et al.   THROMBOSIS AND HAEMOSTASIS

Patient outcomes using the European label for dabigatran

(2013) Andreas Clemens et al.   THROMBOSIS AND HAEMOSTASIS

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

(2012) Scott Kaatz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a “Real-World” Population With Atrial Fibrillation Receiving Anticoagulant Therapy

(2012) Vanessa Roldán et al.   CHEST

Acute management of bleeding in patients on novel oral anticoagulants

(2012) Deborah M. Siegal et al.   EUROPEAN HEART JOURNAL

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

(2012) Renato D Lopes et al.   LANCET

Prothrombin complex concentrate (PCC, Octaplex®) in patients requiring immediate reversal of vitamin K antagonist anticoagulation

(2012) Madeline M. Song et al.   THROMBOSIS RESEARCH

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists

(2011) Chiara Marchesi et al.   THROMBOSIS AND HAEMOSTASIS

Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy

(2011) Ammar Majeed et al.   THROMBOSIS RESEARCH

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation

(2010) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Safety of Recombinant Activated Factor VII in Randomized Clinical Trials

(2010) Marcel Levi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Recombinant Activated Factor VII in Patients Without Hemophilia

(2009) Cyrus C. Hsia et al.   ANNALS OF SURGERY

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prothrombin complex concentrate (Beriplex®P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial

(2008) I. PABINGER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage

(2008) Stephan A. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE